$CPIX

Biotech stocks hit 52-week highs Aug. 10 on trial and earnings updates. Silence Therapeutics (SLN) rose about 29% to $17.58 after Phase 2 SANRECO topline results for divesiran and a reduced Q2 net loss, plus an announced ~$150M ADS offering. AbCellera (ABCL) gained ~34% to $10.01 on Phase 2 ABCL635 data. Cumberland (CPIX) reached $8.45 on Phase 2 Ifetroban progress. Celldex (CLDX) rose to $43.21 on Barzolvolimab Phase 3/2 readouts. Biodesix (BDSX) hit $25.51 after Q2 revenue of $26.9M and FY gui

Cumberland Pharmaceuticals (Nasdaq: CPIX) reported Q2 2026 results and updated investors after closing a strategic transaction with Apotex Health. Apotex acquired Cumberland’s FDA-approved branded portfolio for $100 million plus $11 million for inventory and transition services. Cumberland declared a $1.50 special dividend. Q2 loss was $3.1 million from continuing operations and $4.1 million net. It reported $63 million assets and $4 million cash at June 30.

CUMBERLAND PHARMACEUTICALS INC (CPIX) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 a2026q2-ex991er.htm EX-99.1 Document CUMBERLAND PHARMACEUTICALS REPORTS COMPANY UPDATE & Q2 2026 FINANCIAL RESULTS $100 million Strategic Transaction Closed Special Shareholder Dividend Funded Advancing Late Stage Clinical Pipeline NASHVILLE, Tenn. (Tuesday, August 04,

Biotech gainers on Monday included Universe Pharmaceuticals (UPC), which reported six-month ended March 31, 2026 revenue of $9.03 million and net loss of $1.55 million, and shares rose about 99% to $6.48. Cumberland Pharma (CPIX) rose over 38% ahead of Q2 results after a $100 million branded portfolio sale. Autolus (AUTL) gained about 22% on preliminary Q2 Aucatzyl net product revenue of about $45 million. Other movers included Pulmonx (LUNG), SL Science (SLBT), CAMP4 (CAMP), and Beyond Air (XAI

Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX) declared a special cash dividend of $1.50 per share, payable July 31, 2026 to shareholders of record July 10, 2026. The move follows its Apotex Health strategic transaction, which provided $100 million cash and up to $11 million more. The board also authorized a $5 million buyback.

Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX) issued a corrected PR Newswire release announcing a special cash dividend of $1.50 per share. Record date is July 23, 2026 and payment date is July 31, 2026. The board also authorized an open-market buyback up to $5 million after a $100 million Apotex Health strategic transaction.

Apotex Health Corp. said it has completed its acquisition of Cumberland Pharmaceuticals’ U.S. branded medicines business, adding established brands including Kristalose, Caldolor, Sancuso, Vibativ, Acetadote, Vaprisol and Talicia. Apotex expects the deal to expand its specialty and hospital-focused presence across areas such as oncology and infectious disease. Cumberland Pharmaceuticals is Nasdaq-listed as CPIX.

CUMBERLAND PHARMACEUTICALS INC (CPIX) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. EX-99.2 4 tm2619330d1_ex99-2.htm EXHIBIT 99.2 Exhibit 99.2 UNAUDITED PRO FORMA FINANCIAL INFORMATION The following unaudited pro forma condensed consolidated balance sheet data as of March 31, 2026, is presented to show how the Transaction might have affected the historical finan

CUMBERLAND PHARMACEUTICALS INC (CPIX) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. cpix-20260624 0001087294 false 0001087294 2026-06-24 2026-06-24 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 June 24, 2026 ( June 24, 2026 ) Date of Report (d

Premier Membership includes 4,350 U.S. Hospitals NASHVILLE, Tenn., Oct. 13, 2025 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. ( NASDAQ:CPIX ) , a specialty pharmaceutical company, has added their potent antibiotic, Vibativ® ( telavancin ) , to a national group purchasing agreement with ...